• Robert Friedland, MD

    Robert Friedland, MD is a Professor in Department of Neurology, and is a Mason C. and Mary D. Rudd Endowed Chair In Neurology at University of Louisville School of Medicine, Louisville, KY. He is a devoted clinical and research neurologist focused on dementia, Alzheimer's disease, Parkinson disease and brain aging. He graduated from the Mount Sinai School of Medicine in New York in 1973, and completed his neurology residency at the Mount Sinai Hospital. He was a Fellow in dementia and aging at the Albert Einstein College of Medicine, NY. He served as Chief Neurologist at University California, Berkeley from 1985 to 1990. He was also a Deputy Clinical Director and Chief of the Section on Brain Aging and Dementia of the National Institute on Aging, NIH. He is currently engaged in studies to developing immunological approaches to the treatment of both Alzheimer and Parkinson's diseases.Dr. Friedland has authored or coauthored over 200 scientific publications and has current research funding from the (National Institute on Aging, NIH, as well as several Foundations, Institutes, Corporations and Families.

  • Dinesh Vyas, Ph.D

    Dinesh Vyas has 31 years of industry experience in drug discovery and development. In his tenure at Bristol-Myers Squib, Dr. Vyas participated in the discovery and development of 14 clinical drug candidates with one FDA approved NDA. His contributions earned him the Associate Director, Director, Group Director, and Distinguished Research Fellow positions in BMS. He is an author/coauthor on more than 110 publications and written numerous book chapters and review articles. He is also an inventor/co-inventor on over 40 patents. Currently, he is an active member of the Connecticut Academy of Sciences and Engineering (CASE) and is on the editorial board of Medicinal Research Reviews. He has participated in NIH and CASE study sections.

  • Pushpa D. Singh, Ph. D. CMC Expert

    Dr. Singh is a Pharmaceutical R&D executive with 30 years of experience in all phases of product development, technology transfer, and in product life-cycle management. As an Executive Director at Bristol-Myers Squibb, she led the organization requiring detailed and thorough review of technical information for Quality and GMP Compliance, CMC Technical Documentation, and Environment, Health & Safety. Eventually, as Vice President, Quality Operations & CMC Regulatory at Keryx Biopharmaceuticals, she was responsible for the overall strategic and operational activities in ensuring quality and regulatory compliance in the production and analysis of clinical trial materials. In addition to CMC, Dr. Singh has extensive experience in regulatory agency interactions such as end-of-phase 2 and pre-NDA meetings, and regulatory agency activities in support of investigational and registrational submissions.Dr. Singh received her Ph.D. in Organic Chemistry from MIT, and post doctorate from Oxford University. She has published 17 papers and holds five patents.

  • Dr. Caroline Zeiss, DVM, Ph.D

    Dr. Caroline Zeiss is a Professor of Comparative Medicine and Associate Professor of Ophthalmology at the Yale University School of Medicine. She is also Unit Chief of Pathology and is a veterinary anatomic pathologist with expertise in rodent pathology, neuropathology and comparative ocular pathology.

    Dr. Caroline Zeiss is a Professor of Comparative Medicine and Associate Professor of Ophthalmology at the Yale University School of Medicine. She is also Unit Chief of Pathology and is a veterinary anatomic pathologist with expertise in rodent pathology, neuropathology and comparative ocular pathology.